JDRF Partners with Osiris on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes
New York, NY October 25, 2007 The Juvenile Diabetes Research Foundation announced today a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II clinical trial using Prochymal, an immunomodulatory cell therapy product, to preserve and regenerate insulin-producing cells in patients newly diagnosed with type 1 diabetes .
JDRF, the worlds largest charitable funder of diabetes research, said that it would fund Osiris proof-of-concept trial of Prochymal, a formulation of immunomodulatory adult bone marrow-derived mesenchymal stem cells, in type 1 diabetes.. Prochymal is currently being evaluated by Osiris in Phase III trials for Graft-vs-Host Disease (GVHD) and Crohns Disease.
Maryland-based Osiris Therapeutics is a leading cell-based therapeutic company, whose focus has been on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.
The proposed research from Osiris presents a novel approach for the development of a immunomodulatory cellular therapy, and supports the goals of our program to halt or reverse the autoimmune attack that causes type 1 diabetes, said Teodora Staeva-Vieira, Ph.D., Director of the Autoimmunity Program at JDRF.
JDRF is partnering with Osiris through its innovative Industry Discovery and Development Partnership (IDDP) program. Through the IDDP program, JDRF partners with pharmaceutical, biotech, and medical device businesses with the goal to accelerate the development and commercialization of drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications. Currently, JDRF has funded applied diabetes projects at 22 companies, including Osiris.
Prochymal has shown promise as a therapy for severe
'/>"/>
| Contact: Susan Sherman ssherman@jdrf.org 212-479-7510 Juvenile Diabetes Research Foundation International Source:Eurekalert |